GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024
Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair
ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of the 100th peer-reviewed journal article using the Parsortix® system for the isolation, harvest and analysis of CTCs. The journal article is published by researchers from a leading international referral centre for the treatment and study of cancer, the Fondazione IRCCS – Istituto Nazionale dei Tumori Di Milano (Italy).
The use of whole genomic sequencing and machine learning has allowed researchers to identify key cancer genes associated with DNA proliferation and repair. This groundbreaking research has the potential to revolutionize the way cancer is diagnosed and treated.
By isolating and analyzing CTCs, researchers are able to gain valuable insights into the genetic makeup of tumors, which can lead to more targeted and personalized treatment options for cancer patients. The Parsortix® system has been instrumental in this research, providing a reliable and efficient method for CTC isolation.
How will this affect me:
As a cancer patient, the advancement of whole genomic sequencing and machine learning in identifying key cancer genes can have a significant impact on your treatment plan. By better understanding the genetic mutations driving your cancer, doctors can tailor treatment options that are more effective and have fewer side effects.
How will this affect the world:
The publication of this 100th peer-reviewed journal article marks a significant milestone in the field of liquid biopsy and cancer research. The findings from this research have the potential to improve cancer diagnosis and treatment on a global scale, ultimately leading to better outcomes for patients worldwide.
Conclusion:
With the groundbreaking research using whole genomic sequencing and machine learning, the future of cancer treatment looks promising. The collaboration between ANGLE plc and researchers from the Fondazione IRCCS – Istituto Nazionale dei Tumori Di Milano marks a significant advancement in the fight against cancer. We look forward to seeing how this research continues to impact the field of oncology in the years to come.
